Compare Five9 Inc (FIVN) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Immunovant Inc. Common Stock — how do they compare? Five9 Inc trades at $35.37 (market cap $2.63B), while Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.4× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Immunovant Inc. Common Stock for 0 Days on average.
| FIVN | IMVT | |
|---|---|---|
Market Cap | $2.63B | $6.25B |
Volume | 1,864,393 | 1,755,411 |
Sector | Technology | Health |
52-Week High | $38.65 | $44.96 |
52-Week Low | $13.61 | $17.03 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.78B | $5.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.78, up 1.47% today, with strong technical momentum and consistent earnings beats. Revenue growth accelerated to $1.15B in 2025, with net income turning positive at $39M. The stock shows bullish technical signals with support at $33 and resistance at $34, while AI revenue surged 78% in Q2 2026, driving investor optimism.
Outlook remains positive with 61% analyst buy ratings and $34 consensus target, though high P/E of 51.7 and insider selling pose risks. The company's shift to AI-driven contact center solutions positions it for growth, but competition and valuation concerns require monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
